Current clinical trials examining LuPSMA

“There's a hope that we can modulate PSMA expression with some drugs, increase the amount of PSMA on the tumors, [and] therefore increase the amount of radiation that we can target,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.

In this video, Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS, discusses the current clinical trials highlighted in the lecture, “LuPSMA: The Newest Treatment Class for Advanced Prostate Cancer,” presented recently at the 2021 Prostate Cancer Foundation Scientific Retreat. Hofman is a nuclear medicine physician and director of PROSTIC, Melbourne, Australia.